Rinatabart sesutecan (Rina-S; GEN1184)

2026-05-21 — Genmab A/S (Nasdaq: GMAB) announced it will present/publish 23 abstracts at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago) and the 2026 EHA Congress (June 11–14, Stockholm). Twenty abstracts relate to epcoritamab (CD3xCD20 subcutaneous bispecific; marketed as EPKINLY/TEPKINLY for certain lymphoma indications), with four oral presentations. Featured data include full Phase 3 EPCORE DLBCL-1 results comparing epcoritamab monotherapy vs investigator’s choice chemotherapy in relapsed/refractory large B-cell lymphoma, plus additional Phase 3 EPCORE FL-1 data for epcoritamab + rituximab/lenalidomide (R²) vs R² alone in relapsed/refractory follicular lymphoma; additional real-world and health economics/outcomes research are also planned. Three abstracts highlight trials-in-progress for late-stage investigational assets rinatabart sesutecan (Rina‑S; FRα-targeted ADC; Phase 3 in ovarian/endometrial cancer) and petosemtamab (EGFRxLGR5 bispecific; Phase 2 in PD‑L1–high metastatic NSCLC and other tumors). The announcement underscores Genmab’s pipeline breadth and potential label-expansion pathways for epcoritamab.